PMID- 22008315
OWN - NLM
STAT- MEDLINE
DCOM- 20120703
LR  - 20191210
IS  - 1347-4820 (Electronic)
IS  - 1346-9843 (Linking)
VI  - 76
IP  - 1
DP  - 2012
TI  - Urinary 8-hydroxy-2'-deoxyguanosine as a novel biomarker for predicting cardiac 
      events and evaluating the effectiveness of carvedilol treatment in patients with 
      chronic systolic heart failure.
PG  - 117-26
AB  - BACKGROUND: The authors recently reported that urinary 
      8-hydroxy-2'-deoxyguanosine (U8-OHdG) derived from cardiac tissue reflects 
      clinical status and cardiac dysfunction severity in patients with chronic heart 
      failure (CHF). The aim of the present study was to investigate whether U8-OHdG 
      levels can accurately predict cardiac events in CHF patients and their response 
      to beta-blocker treatment. METHODS AND RESULTS: Plasma brain natriuretic peptide 
      (BNP) and U8-OHdG levels were measured in 186 consecutive CHF patients before 
      discharge. Patients were then prospectively followed (median follow-up, 649 days) 
      with endpoints of cardiac death or hospitalization due to progressive heart 
      failure. From receiver operating characteristic curve analysis, cut-offs were 
      12.4ng/mg creatinine (Cr) for U8-OHdG and 207pg/ml for BNP. On multivariate Cox 
      analysis, U8-OHdG and BNP were independent predictors of cardiac events. Patients 
      were classified into 4 groups according to U8-OHdG and BNP cut-offs. The hazard 
      ratio for cardiac events in patients with BNP >/=207pg/ml and U8-OHdG >/=12.4ng/mg Cr 
      was 16.2 compared with approximately 4 for patients with only 1 indicator above 
      its respective cut-off. Furthermore, carvedilol therapy was initiated in 30 CHF 
      patients. In responders (>/=10% increase in left ventricular ejection fraction 
      [LVEF] or >/=1 class decrease in New York Heart Association [NYHA] class), U8-OHdG 
      levels decreased significantly along with improved NYHA class, LVEF, and BNP 
      levels after treatment. CONCLUSIONS: U8-OHdG may be a useful biomarker for 
      predicting cardiac events and evaluating beta-blocker therapy effectiveness in CHF 
      patients.
FAU - Susa, Takehisa
AU  - Susa T
AD  - Division of Cardiology, Department of Medicine and Clinical Science, Yamaguchi 
      University Graduate School of Medicine, Ube, Japan.
FAU - Kobayashi, Shigeki
AU  - Kobayashi S
FAU - Tanaka, Takeo
AU  - Tanaka T
FAU - Murakami, Wakako
AU  - Murakami W
FAU - Akashi, Shintaro
AU  - Akashi S
FAU - Kunitsugu, Ichiro
AU  - Kunitsugu I
FAU - Okuda, Shinichi
AU  - Okuda S
FAU - Doi, Masahiro
AU  - Doi M
FAU - Wada, Yasuaki
AU  - Wada Y
FAU - Nao, Tomoko
AU  - Nao T
FAU - Yamada, Jutaro
AU  - Yamada J
FAU - Ueyama, Takeshi
AU  - Ueyama T
FAU - Okamura, Takayuki
AU  - Okamura T
FAU - Yano, Masafumi
AU  - Yano M
FAU - Matsuzaki, Masunori
AU  - Matsuzaki M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20111019
PL  - Japan
TA  - Circ J
JT  - Circulation journal : official journal of the Japanese Circulation Society
JID - 101137683
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Biomarkers)
RN  - 0 (Carbazoles)
RN  - 0 (Propanolamines)
RN  - 0K47UL67F2 (Carvedilol)
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - 88847-89-6 (8-Hydroxy-2'-Deoxyguanosine)
RN  - G9481N71RO (Deoxyguanosine)
SB  - IM
MH  - 8-Hydroxy-2'-Deoxyguanosine
MH  - Adrenergic beta-Antagonists/*therapeutic use
MH  - Adult
MH  - Aged
MH  - Biomarkers/blood/urine
MH  - Carbazoles/*therapeutic use
MH  - Carvedilol
MH  - Chronic Disease
MH  - Death, Sudden, Cardiac/*epidemiology
MH  - Deoxyguanosine/*analogs & derivatives/urine
MH  - Female
MH  - Follow-Up Studies
MH  - Heart Failure, Systolic/*drug therapy/*mortality/urine
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/blood
MH  - Predictive Value of Tests
MH  - Propanolamines/*therapeutic use
MH  - Prospective Studies
MH  - Risk Factors
MH  - Treatment Outcome
EDAT- 2011/10/20 06:00
MHDA- 2012/07/04 06:00
CRDT- 2011/10/20 06:00
PHST- 2011/10/20 06:00 [entrez]
PHST- 2011/10/20 06:00 [pubmed]
PHST- 2012/07/04 06:00 [medline]
AID - JST.JSTAGE/circj/CJ-11-0537 [pii]
AID - 10.1253/circj.cj-11-0537 [doi]
PST - ppublish
SO  - Circ J. 2012;76(1):117-26. doi: 10.1253/circj.cj-11-0537. Epub 2011 Oct 19.